EUCOPE – the European Confederation of Pharmaceutical Entrepreneurs
EUCOPE provides a platform for discussion for pharmaceutical entrepreneurs. On a regular basis owners and CEOs of pharmaceutical companies and associations discuss solutions to improve the quality of life for patients and to strengthen the competitiveness of the European pharmaceutical industry.
The legal framework for pharmaceutical markets is set largely by the EU institutions. An active role in the political debate on the EU level is therefore more important than ever before. The early perception of future markets and reliable regulatory circumstances are key aspects for entrepreneurial success.
Knowledge about this legal framework and the active discussion and participation on the EU level is therefore essential for pharmaceutical entrepreneurs in order to generate innovations.
EUCOPE understands itself as service provider for its members. The association provides its members with an early understanding about regulatory developments. Current topics are:
- Commission assessment of the regulatory incentives for the development of medicinal products
- EU cooperation on Health Technology Assessment
- Implementation of the new Clinical Trials Regulation (Regulation (EU) No 536/2014)
- EMA Transparency Policy (Policy 0070)/New Implementation Guidance
- New Medical Devices Regulation and New IVD Regulation
A tight monitoring and comprehensive information about future market conditions are valuable assets for entrepreneurial decisions. Questions such as access to finance, market access and reliable reimbursement conditions are of crucial importance for pharmaceutical entrepreneurs. Please find out more about EUCOPE under About us.
Conferences and Working Groups
EUCOPE Members’ Meeting, 27 June, Brussels
Regulatory/Pharmacovigilance/Medical Device Working Group, 30 August, Brussels
Pricing & Reimbursement/Market Access Working Group, 11 September, Brussels
EUCOPE Members’ Meeting, 16 October, Brussels
Orphan Medicinal Products Working Group, 24 October, Brussels
Pricing & Reimbursement/Market Access Working Group, 20 November, Brussels